Bristol Basks In Broad Ipilimumab Label, Sets High Price
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling does not specify line of therapy, so the melanoma drug could see use beyond very late-stage refractory patient population studied in pivotal trial.